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OBJECTIVES: The purpose of this study was to evaluate the
impact of mesalazine on patient reported QoL when adminis-
tered either orally or in combination with topical treatment in
patients with acute, mild-to-moderate ulcerative colitis (UC).
METHODS: Data was from a randomised controlled trial where
patients received daily treatment of either 4 g oral mesalazine
plus 1 g enema mesalazine (MES+), or 4 g oral mesalazine plus a
placebo enema (MES-). Oral treatment was given for 8 weeks
(the trial period) and enema treatment for the initial 4 weeks
only. QoL was measured using the EQ-5D and administered at
baseline, 2, 4, and 8 weeks. The Mann-Whitney test was used to
compare means. RESULTS: 127 subjects were randomised: 60%
male, mean age 43.5 years and mean EQ-5D index value 0.765
(SD 0.16). The baseline EQ-5D was 0.780 (SD 0.20) in the MES+
arm and 0.745 (SD 0.16) in the MES- arm (p = 0.27). Rapid
improvement in QoL was evident in both treatment arms at 2
weeks with change from baseline Db = 0.079 (p < 0.001) in the
MES+ arm and Db = 0.097 (p = 0.03) in the MES- arm.
However, a near normal QoL was achieved more quickly in the
MES+ arm, whereby the mean QoL at 4 weeks was 0.921 (SD
0.14), versus 0.859 (SD 0.17) in the MES- arm (p = 0.034). At 8
weeks, substantial improvement in QoL was evident in both
treatment arms with almost normal QoL compared to the
UK standard population (MES+: mean = 0.922, Db = 0.15
[p < 0.001] and MES-: mean = 0.920, Db = 0.16 [p < 0.001]).
CONCLUSION: Treatment with mesalazine resulted in
improved QoL as measured using the EQ-5D. Near normal QoL
was achieved by 8 weeks in the two treatment arms but it was
achieved much faster with combination treatment of oral and
enema mesalazine. Consequently combination oral and enema
therapy should be offered as ﬁrst line therapy for patients with
mild-to-moderate UC.
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OBJECTIVES: Our aim was to compare the costs and effects of
post-surgical parecoxib plus opioid treatment with opioid only
analgesia over 3 days. METHODS: The analgesic safety and
efﬁcacy of intravenous parecoxib was evaluated in a randomized,
double-blind clinical trial. Patients undergoing major orthopedic,
abdominal, gynecologic, or noncardiac thoracic surgery requir-
ing anesthesia received either 40 mg parecoxib on the day of
surgery, then 20 mg parecoxib every 12 hours for 3 days or
matching placebo. Patients also received standard regimen of
opioids on demand for supplemental analgesia. Placebo patients
consumed signiﬁcantly more opioids, had signiﬁcantly higher
mean pain ratings on each study day and reported signiﬁcantly
more opioid-related symptom distress than parecoxib patients.
Effects were measured as the sum of pain intensity (SPI) scores
over a 24 hour period. Once daily, using four-point scales,
patients also rated their distress from opioid-related adverse
events (AEs) in terms of frequency, severity, and degree of bother.
An AE was deﬁned as clinically meaningful event (CME) based
on a severity rating of “severe” or “very severe” for all AEs
except confusion, which was deﬁned by ratings from “moderate”
to “very severe.” A treatment model based on clinical practice in
the UK obtained through a clinician panel was developed incor-
porating opioid use and impact of CMEs on resource use.
RESULTS: Parecoxib achieved 1.36 days reduction in length of
hospital stay, and 0.41 and 1.80 hours reduction in physician and
nurse time, respectively. Parecoxib cost £16.25 over 3 days,
however reduced the costs of opioid use by £0.21 and the cost of
treatment of opioid-related CMEs by £429.80. Parecoxib also
reduced SPI scores by 21.6 points over this period, therefore
dominated opioid only analgesia. CONCLUSION: Parecoxib is
useful adjunct to opioids in noncardiac surgical patients improv-
ing postoperative analgesic management, reducing opioid need,
opioid-related AEs and lowering treatment costs.
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OBJECTIVES: The UK has recently implemented a system
of prospective payment for episodes of care (Health Related
Groups). When conducting economic evaluations alongside clini-
cal trials, costs for episodes of care may not prove adequate
estimates for procedure costs. The purpose of this study was to
collect data on resource use for procedures related to intracere-
bral haemorrhage (ICH) and calculate their respective cost.
METHODS: A questionnaire was developed to capture resource
use for 15 surgical procedures related to ICH. This covered all
aspects of inpatient treatment including theatre time, inpatient
consultations, rehabilitative therapy, disposables, diagnostic
investigations, drugs and length of stay (LOS). Three UK consult-
ants with a speciality in ICH responded to the questionnaire.
Using a bottom-up costing approach, unit costs from publicly
available sources were ascribed to each resource, which were
summed to calculate the total average cost per procedure.
RESULTS:The average cost of major ICHprocedures—aneurysm
clipping, aneurysm coiling, craniotomy for haematoma and
decompressive craniectomy—was £11,473, £12,220, £12,113
and £18,650, with LOS being the primary cost driver (44–75% of
total costs, ranging between £5,389 and £12,616). The exception
to this was aneurysm coiling, where LOSwas reduced but the coils
themselves accounted for 30% of total cost making the procedure
slightly more expensive than the most common alternative of
aneurysm clipping. For secondary procedures, costs ranged
between £1,646 for tracheostomy and £6,823 for burrhole aspi-
ration of haematoma. LOS remained the dominant factor but
consumables played a signiﬁcant role contributing an average of
37% to total costs. CONCLUSION: LOS is the main cost driver
for procedures related to acute care for ICH, followed by consum-
ables. Cost estimates obtained through micro-costing can be used
for trial-based economic evaluations. They could also assist phy-
sicians and hospital administrators to better understand the true
impact of procedures on real hospital spending.
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